$55M Equity Rights Offering oversubscribed
Company: Core Scientific
The claim, verbatim
Core Scientific's $55 million Equity Rights Offering was oversubscribed, with aggregate subscriptions including oversubscriptions exceeding the $55 million cap; the subscription period expired January 5, 2024.
Source (primary)
core-scientific 8-K exhibit (d109221dex992.htm) (SEC EDGAR (8-K Ex), press_release)
View cached copy (2026-11-15)Live source ↗
Quote: “The ERO was oversubscribed, and the aggregate subscriptions (including oversubscriptions) exceeded $55 million at which the ERO is capped.”
How we checked this
Checked on November 16, 2026. The cited source supports every part of this claim.
The press release states the $55 million offering was oversubscribed, that subscriptions exceeded the $55 million cap, and that the subscription period expired at 5:00 P.M. Eastern Time on January 5, 2024.
Confirmed in the source:
- Core Scientific's Equity Rights Offering was $55 million
- The Equity Rights Offering was oversubscribed
- Aggregate subscriptions, including oversubscriptions, exceeded the $55 million cap
- The subscription period expired on January 5, 2024
What we did: Read our cached copy of SEC EDGAR (8-K Ex) (https://www.sec.gov/Archives/edgar/data/1839341/000119312524004018/d109221dex992.htm) in full (6,982 characters, retrieved November 15, 2026) and checked each assertion in the claim against it.
Additional evidence
confirms core-scientific 8-K exhibit (d109221dex992.htm)
Quote: “The ERO was oversubscribed, and the aggregate subscriptions (including oversubscriptions) exceeded $55 million at which the ERO is capped.”